Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8IX30
UPID:
SCUB3_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IX30; A8K5A3; Q5CZB3; Q86UZ9; Q8NAU9
Background:
Signal peptide, CUB and EGF-like domain-containing protein 3 plays a pivotal role in the BMP signaling pathway, essential for chondrogenesis, osteogenesis, and skeletal development. It acts as a coreceptor for BMP ligands, enhancing their interaction with BMP type I receptors. This protein's involvement in the TGFBR2 signaling pathway underscores its significance in epithelial-mesenchymal transition and cancer progression.
Therapeutic significance:
Given its crucial role in skeletal anomalies and potential involvement in cancer progression, targeting Signal peptide, CUB and EGF-like domain-containing protein 3 could offer novel therapeutic avenues for treating Short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 2, as well as certain cancers.